louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04339322: Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt
Official title: Characteristics and Outcome of COVID-19 Among Egyptian Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Characteristics Diseases
Outcome, Fatal
Keywords: Covid-19
characteristics
Outcome
Egypt
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-04-09
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with clinical presentation and confirmed as Covid-19 according to the definition of Egyptian Ministry of Health.

Brief summary: The World Health Organization (WHO) has recently declared coronavirus disease 2019 (Covid-19) a public health emergency of international concern. Egypt is one of the countries that has been infected by Covid-19. The characteristics of clinical presentation, laboratory and radiological data are not yet studied. Outcomes of covid-19 in Egypt also have not been described yet.

Detailed description: Patients admitted to Assiut University hospital, Al Rajhi liver hospital and other covid-19 Quarantine hospitals will be included. The characteristics of patients will be described such as demographic data; age, sex,history of contact to COVID-19 patients or traveling abroad and their clinical manifestation such as fever,cough,shortness of breath, sore throat, diarrhea. Laboratory data will also be included such as blood picture,D-Dimer, serum ferritin, creatinine, liver enzymes, oxygen saturation and covid-19 polymerase chain reaction (PCR). Radiological data will be described as regarding chest X-ray and/or computed tomography.

Patients will be followed until complications, improvement, transfer to another hospital or death and their outcome will be described.

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of Covid-19 .

Exclusion Criteria:

* Patients refuse to participate in the study

Primary outcomes:
measure: Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group
timeFrame: 2 months
measure: Clinical manifestations of Coronavirus Disease 2019 (COVID-19)
timeFrame: 2 month
measure: Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort
timeFrame: 2 months
measure: Radiological features of Coronavirus Disease 2019 (COVID-19) cohort
timeFrame: 2 month
Secondary outcomes:
measure: outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group
timeFrame: 1 week
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00275522: The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
Official title: A Randomized Open-label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens With a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Transplant
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Wyeth is now a wholly owned subsidiary of Pfizer
First posted: 2006-01-12
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is being done to compare the safety and effects (good and bad) of three different combinations of immunosuppression drugs used by kidney transplant recipients while also looking at their kidney function.

Detailed description: This is an open-label, randomized, comparative, multinational study. The study will be looking at the kidney function of kidney transplant recipients, while also comparing the safety and the effects (good and bad) of three different combinations of immunosuppression drugs in combination with prednisone, following treatment with Daclizumab (Zenapax). The three combinations are; (1) sirolimus and tacrolimus followed by the withdrawal of tacrolimus after three months; (2) sirolimus and mycophenolate mofetil (MMF); and (3) tacrolimus and MMF. The participants will be required to return to throughout the next 24 months following their transplant for physical exams, chest x-ray, blood, and urine tests. Participants will be put into one of three groups, and receive the study drugs starting on the day of transplant. Due to some drugs affecting the drug levels of sirolimus, participants need to agree not to take any new drugs during the study unless approved by the study doctor.

Eligibility criteria: Participants must be at least between the ages of 18 and 75, and will be receiving their first or second kidney transplant.

Primary outcomes:
measure: Calculated creatinine clearance at 12 months after transplantation.
Secondary outcomes:
measure: Calculated creatinine clearance at 26, 78, and 104 weeks post transplantation.
measure: Serum creatinine at 26, 52, 78, and 104 weeks post transplantation.
measure: Subject and graft survival at 26, 52, 78, and 104 weeks post transplantation.
measure: Incidence and severity of biopsy-confirmed acute rejection at 26, 52, 78, and 108 weeks post transplantation.
measure: Severity of rejection, including histological grade of the first acute rejection episode.
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Mark D. Stegall, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06857422: Dyspnea and Psychosocial Effects of Hand Fan Application in COPD Patients
Official title: Effect of Hand Fan Applied to COPD Patients on Dyspnea, Illness Perception, Anxiety and Depression: a Double-Blind Randomized Controlled Experimental Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: COPD
Dyspnea
Illness Perception
Anxiety
Depression
Lead sponsor: Ardahan University
Sponsor class: OTHER
First posted: 2025-03-04
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized controlled trial aims to evaluate the effects of hand fan application on dyspnea, illness perception, anxiety, and depression in COPD patients. A total of 56 voluntary COPD patients (28 experimental, 28 control) will be recruited from Ardahan State Hospital Chest Diseases Clinic.

Patients will be randomly assigned to the experimental or control group. The experimental group will receive a hand fan and use it for 10 minutes daily for six weeks, while the control group will receive standard care. Dyspnea, illness perception, anxiety, and depression will be assessed using the Visual Dyspnea Scale, Illness Perception Questionnaire, and Hospital Anxiety and Depression Scale at baseline and after six weeks.

Data will be analyzed using statistical software. This study is expected to contribute to the literature by evaluating a non-pharmacological intervention for COPD-related dyspnea and psychological outcomes.


Eligibility criteria: Inclusion Criteria:

* Orientation and cooperation
* No communication problems

Exclusion Criteria:

* Having a COPD exacerbation in the last 4 weeks

Primary outcomes:
measure: Dyspnea Severity
timeFrame: Pre-intervention: Before the start of the intervention (baseline measurement).Post-intervention: After 6 weeks of intervention (final measurement).
Secondary outcomes:
measure: Illness Perception
timeFrame: Pre-intervention: Before the start of the intervention (baseline measurement).Post-intervention: After 6 weeks of intervention (final measurement).
measure: Anxiety and Depression
timeFrame: Pre-intervention: Before the start of the intervention (baseline measurement).Post-intervention: After 6 weeks of intervention (final measurement).
Other outcomes:
Locations:
city: Ardahan
country: Turkey
facility: Derya ŞİMŞEKLİ
Study officials:
References:
Clinical trial NCT04904822: Abdominal Versus Vaginal Bisection in Laparoscopic Hysterectomy
Official title: Abdominal Versus Vaginal Uterine Bisection for Retrieval of Large Uteri During Laparoscopic Hysterectomy: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hysterectomy
Laparoscopy
Uterine Bisection
Large Uteri
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2021-05-27
Enrollment: 66
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 groups parallel allocation
Primary purpose: TREATMENT

Brief summary: Large uteri present a challenge during Total lap.hysterectomy and its extraction is another challenge. This study addressees and compare 2 methods of retrieval of large uteri

Detailed description: Despite a number of publications about TLH for large uterus, few surgeons have compared the results of their technique of TLH through the vagina or abdominal bisection. The aim of this study was to compare the clinical results of TLH for large uterus through transvaginal or abdominal bisection approaches after strict preoperative assessment.

Eligibility criteria: Inclusion Criteria:

* large uterus ≥ 12weeks,
* benign pathology,
* mobile uterus
* BMI less than 30kg/m2

Exclusion Criteria:

* unfit for laparoscopy,
* Extensive pelvic adhesions,
* Extensive endometriosis
* malignancy
* virgin cases

Primary outcomes:
measure: Retrieval time of uterus
timeFrame: 6 months
measure: Blood loss
timeFrame: 6 months
Secondary outcomes:
measure: Injury of other organs
timeFrame: 6 months
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: Gharbia
Study officials:
References:
Clinical trial NCT00161122: Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)
Official title: Effectiveness and Costs of Combined Influenza and Pneumococcal Vaccination in Pre-School Children With Recurrent Respiratory Tract Infections (RTI): a General Practice-Based Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
Collaborators: name: Netherlands Organisation for Scientific Research
First posted: 2005-09-12
Enrollment: 660
Sex: ALL
Minimum age (years): 18
Maximum age (years): 72
Standard ages: CHILD
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The PRIMAKid trial is a general practice based double-blind randomized placebo-controlled trial on the effectiveness and costs of combined influenza and pneumococcal vaccination in pre-school children with recurrent respiratory tract infections. A target number of 660 children aged 18-72 months with a history of two or more general practitioner attended episodes of RTI, are included. Exclusion criteria are diseases accompanied by a high risk of recurrent RTI and conditions chronically treated with corticosteroids. Over a period of 7 to 22 months follow-up, the number of febrile RTI-episodes as primary outcome is assessed, and as secondary outcomes the severity and length of febrile RTI-episodes, medical visits / interventions, health-related quality of life and productivity loss of parents.


Eligibility criteria: Inclusion Criteria:

* Age between 18-72 months
* A history of two or more episodes of general practitioner attended RTIs

Exclusion Criteria:

* No intention to move within 12 months to another region
* Provision of informed consent
* Good mastering of the Dutch language
* Absence of chronic diseases such as asthma treated with corticosteroids or high-risk disease (such as palatoschisis, Down syndrome, cystic fibrosis, etc.)
* No previous influenza vaccination or pneumococcal vaccination or Hepatitis B vaccination
* No hypersensitivity to eggs and/or antibiotics, and/or serious history of serious adverse events through vaccination

Primary outcomes:
measure: number of febrile RTI-episodes
Secondary outcomes:
measure: severity and length of febrile RTI-episodes as well as medical consumption
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
Study officials:
affiliation: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
name: Eelko Hak, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schonbeck Y, Sanders EA, Hoes AW, Schilder AG, Verheij TJ, Hak E. Rationale and design of the prevention of respiratory infections and management in children (PRIMAKid) study: a randomized controlled trial on the effectiveness and costs of combined influenza and pneumococcal vaccination in pre-school children with recurrent respiratory tract infections. Vaccine. 2005 Sep 30;23(41):4906-14. doi: 10.1016/j.vaccine.2005.05.021.
Clinical trial NCT04088422: Cell Free DNA in Mature B-cell Lymphoma
Official title: Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Mature B-Cell Lymphoma
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2019-09-12
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with diagnosis of mature B-cell tumor according to WHO 2008 criteria without any previous treatment in Ruijin Hospital would be included.

Brief summary: The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.


Eligibility criteria: Inclusion Criteria:

* Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
* 18 years or older

Exclusion Criteria:

* Chemotherapy before
* Other tumors

Primary outcomes:
measure: progression free survival
timeFrame: 2-year
Secondary outcomes:
measure: overall survival
timeFrame: 2-year
measure: Complete Response rate
timeFrame: 6 weeks after treatment
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin hospital
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Weili Zhao, MD，PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03034122: Is Caffeine an Environmental Modifier in Huntington's Disease?
Official title: Is Caffeine an Environmental Modifier in Huntington's Disease?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Huntington Disease
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 100
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: premanifest HD subjects

Brief summary: The aim of the study is to establish if caffeine consumption is associated with the evolution of the disease in premanifest HD.


Eligibility criteria: Inclusion Criteria:

* HD mutation carriers (\>36 CAG)
* premanifest (total motor UHDRS \< 5)
* estimated time to diagnosis between 3 and 10 years
* adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years)
* informed consent signed
* with a social protection

Exclusion Criteria:

* MRI contraindication
* pregnant and lactating women
* People under guardianship, trusteeship, deprive of freedom

Primary outcomes:
measure: Change in striatal volume
timeFrame: at 2 years
Secondary outcomes:
measure: Unified Huntington's Disease Rating Scale (UHDRS)
timeFrame: at 1 years, at 2 years
measure: SDMT -symbol digit modality test
timeFrame: at 1 years, at 2 years
measure: Stroop test
timeFrame: at 1 years, at 2 years
measure: PBA (problem behaviors assessment)
timeFrame: at 1 years, at 2 years
measure: score at Epworth sleepiness scale
timeFrame: at 1 years, at 2 years
measure: MRI
timeFrame: at 1 years, at 2 years
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU de Amiens
city: Angers
country: France
facility: CHU de Angers
city: Bordeaux
country: France
facility: CHU Pellegrin
city: Grenoble
country: France
facility: CHU de Grenoble
city: Lille
country: France
facility: Hôpital Roger Salengro, CHRU
city: Montpellier
country: France
facility: CHU Montpellier
city: Nancy
country: France
facility: CHU de Nancy
city: Paris 14
country: France
facility: AH-HP La Pitié-Salpétrière
city: Paris
country: France
facility: AH-HP, Hôpital Henri Mondor
city: Toulouse
country: France
facility: CHU Purpan
Study officials:
affiliation: University Hospital, Lille
name: Clémence Simonin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03577522: Comparison of Two Hydroxy-apatite Coated Hip Stems
Official title: Randomized Controlled Trial Comparison of Two Hydroxy-apatite Coated Hip Stems Utilizing Radiostereometric Analysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hip Osteoarthritis
Lead sponsor: Canadian Radiostereometric Analysis Network
Sponsor class: OTHER
First posted: 2018-07-05
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In this study, the investigators propose to randomize 80 subjects to receive either the Avenir cementless hip stem or a competing, HA-coated hip stem (Corail, DePuy-Synthes) and follow these patients for a period of 2 years post-surgery. The investigators aim to determine if the Avenir cementless hip stem has equivalent or better fixation and clinical outcomes compared to a predicate hip stem with longer clinical history.

Detailed description: This is a multi-center, randomized controlled trial of patients undergoing primary total hip arthroplasty. This study will be focused on enrollment at a single site with possible expansion to additional centers should patient enrollment occur at a slower than expected rate. Decision to expand the study to additional centers will be mutually agreed upon by both the clinical site and the study sponsor.

Patients will be randomized to two study groups:

1. Zimmer Avenir cementless, HA-coated femoral hip stem with matching Trilogy IT cup;
2. DePuy-Synthes Corail cementless, HA-coated, non-collared femoral hip stem with matching Pinnacle cup Patient allocation to the study groups will occur following a randomized 4-block design.

Eligibility criteria: Inclusion Criteria

* Symptomatic osteoarthritis of the hip undergoing primary total hip arthroplasty
* Between the ages of 18 and 79 inclusive
* Patients willing and able to comply with follow-up requirements and self-evaluations
* Ability to give informed consent

Exclusion Criteria

* Requires specialty implant (e.g., suspected metal allergy, coxa vera implant)
* Avascular necrosis
* Unresolved infection of the hip
* Hip fracture
* Hip dysplasia
* At risk for loss to follow-up
* Prior surgery to the ipsilateral hip
* Severe proximal femoral deformity preventing the use of standard proximal press-fit femoral components
* Medical condition precluding major surgery
* Current or pending patient incarceration

Primary outcomes:
measure: Migration
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Winnipeg
country: Canada
facility: Concordia Hospital
state: Manitoba
Study officials:
affiliation: Concordia Joint Replacement Group
name: Thomas Turgeon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00934622: Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL
Official title: Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric Intraocular Lens (IOL)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Keywords: AcrySof
ReSTOR
Aspheric IOL
Cataract
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2009-07-08
Enrollment: 76
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will involve up to 20 bilateral patients per surgeon. Patients will be assessed pre-operatively, and at subsequent visits (following the implantation of the intraocular lens in the second eye) at 1 week, 1 month, 3 months and 6 months post-operatively.


Eligibility criteria: Inclusion Criteria:

* 21 years or older;
* need spherical correction between 10-30 Diopters (D);
* corneal astigmatism less than 0.75D as measured by keratometry;
* willing to sign an Informed Consent Form and complete all visits;
* pupil dilation greater than 6mm;
* expected Visual Acuity (measured in logMAR)=0.3 or better

Exclusion Criteria:

* Women of childbearing potential;
* irregular corneal astigmatism;
* keratopathy/keratectasia;
* cornea inflammation or edema;
* cornea reshaping surgery;
* corneal dystrophy;corneal transplant;
* amblyopia;
* glaucoma;
* Retinal Pigment Epitheliopathy (RPE)/Macular changes;
* proliferative diabetic retinopathy

Primary outcomes:
measure: Visual Acuity
timeFrame: pre-operative;1 week,1 month, 3 months and 6 months after 2nd eye surgery
Secondary outcomes:
measure: Spectacle Independence
timeFrame: pre-op;1 week,1 month,3 months and 6 months after 2nd eye surgery
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Alcon Call Center for Trial Locations
state: Texas
Study officials:
References:
Clinical trial NCT06626022: Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Official title: A Phase 3, Multicenter, International, Non-inferiority, Randomized Clinical Trial Comparing Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging (MUSIC-Screen)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Prostate Cancer Screening
Lead sponsor: University of Alberta
Sponsor class: OTHER
First posted: 2024-10-03
Enrollment: 1284
Sex: MALE
Minimum age (years): 50
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.


Eligibility criteria: Inclusion Criteria:

1. Male sex;
2. Age 50-70;
3. PSA 3-20 and/or abnormal DRE;
4. Biopsy naïve.

Exclusion Criteria:

1. Prior personal history of prostate cancer;
2. Prior prostate imaging using microUS or MRI;
3. Contraindication to microUS or MRI;
4. Testosterone replacement therapy within last 12 months; or
5. Androgen deprivation therapy within last 12 months.

Primary outcomes:
measure: Detection of Clinically significant prostate cancer.
timeFrame: Once enrolled, men will be followed for 1 year after the imaging test.
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: University of California, Los Angeles (UCLA)
state: California
city: Edmonton
country: Canada
facility: University of Alberta
state: Alberta
city: Vancouver
country: Canada
facility: University of British Columbia
state: British Columbia
city: Montréal
country: Canada
facility: CIUSSS du Nord-de-l'Île-de-Montréal
state: Quebec
Study officials:
References: